Cartalax Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is Cartalax?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Cellular senescence, connective tissue homeostasis, cartilage biology, epigenetic gene regulation, kidney cell aging, dermal fibroblast research
• First Developed: 1990s, by Professor Vladimir Khavinson
• Molecular Weight: 333.29 g/mol
• Research Status: Preclinical; primarily cell culture and animal model studies; no published Phase II or III human clinical trials
• Key Mechanisms: DNA minor groove binding, senescence marker downregulation, extracellular matrix homeostasis, anti-apoptotic signaling
• Published Studies: Multiple peer-reviewed publications from Russian and international research groups; largest body of work in aging cell biology and connective tissue models
• Clinical Trial Status: No registered human clinical trials identified in ClinicalTrials.gov; some use described in Russian clinical research literature
• Regulatory Classification: Research use only; not approved for human therapeutic application by FDA or EMA

What is Cartalax?

Cartalax is a synthetic tripeptide composed of three amino acids: alanine, glutamic acid, and aspartic acid, abbreviated as AED or designated T-31 in some research literature. It belongs to a class of short regulatory peptides called bioregulators, developed through the work of Professor Vladimir Khavinson and colleagues in Russia beginning in the 1990s. Khavinson’s group pioneered a research program centered on isolating short peptide sequences from organ and tissue extracts, hypothesizing that these sequences carry tissue-specific regulatory signals capable of influencing gene expression in aging cells.

The origins of Cartalax are described in two contexts across research sources. Some documents identify it as derived from cartilage tissue extracts, while others place its isolation in kidney tissue. This discrepancy likely reflects the peptide sequence appearing across multiple tissue types, consistent with its amino acid motif being found in the alpha-1 chain of type XI collagen, a structural protein central to cartilage organization and extracellular matrix integrity. Regardless of source tissue, the synthesized form studied today is a defined three-amino-acid sequence produced under controlled laboratory conditions.

What drew researchers to Cartalax was its atypical mechanism. Most bioactive peptides studied in aging research act on receptors at the cell surface, triggering intracellular cascades from outside the cell. Cartalax, at just 333 daltons, is small enough to penetrate cellular and nuclear membranes directly. Once inside the nucleus, it binds to specific DNA sequences in the minor groove, positioning it as a transcription-level regulator rather than a signaling molecule. This places Cartalax research at the intersection of peptide biochemistry and epigenetics, two fields with growing overlap in aging science.

The research interest in Cartalax connects to broader questions in geroscience: whether short peptide sequences can reverse or delay the molecular hallmarks of cellular aging. Senescent cells accumulate during aging, secreting inflammatory signals and reducing tissue regenerative capacity. Cartalax studies investigate whether modulating the gene expression profile of aging cells, particularly through p53, p16, p21, and SIRT-6 targets, can shift cells toward more youthful functional states. Fibroblasts, chondrocytes, kidney epithelial cells, and mesenchymal stem cells have all served as research models in published studies.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

Cartalax is exceptionally small by peptide standards. At 333 daltons, it falls well below the molecular weight threshold at which most peptides require receptor-mediated mechanisms to enter cells. This size permits passive diffusion across plasma membranes and nuclear envelopes, a property directly relevant to its proposed mechanism of action at the DNA level.

The two acidic residues in its sequence, glutamic acid and aspartic acid, carry negative charges at physiological pH. These charged side chains interact favorably with the electropositive environment of the DNA minor groove, particularly at AT-rich sequences. Molecular modeling studies have identified d(ATATATATAT)2 as a preferred binding target, suggesting the peptide recognizes and stabilizes specific genomic regions rather than acting nonspecifically [1].

The Ala-Glu-Asp sequence corresponds to a motif present in the alpha-1 chain of type XI collagen. Type XI collagen is a quantitatively minor but structurally critical component of cartilage extracellular matrix, regulating fibril diameter and organization in hyaline cartilage. Researchers hypothesize this structural homology contributes to Cartalax’s apparent affinity for connective tissue cell types, though direct receptor binding to collagen-associated proteins has not been confirmed in published literature [2].

Unlike larger bioregulatory peptides that degrade rapidly in aqueous environments, Cartalax shows relative stability under standard storage conditions. The compact three-amino-acid structure offers fewer sites for proteolytic cleavage than longer sequences, which may contribute to measurable biological activity in both in vitro and in vivo experimental contexts.

Mechanisms of Action Being Investigated

Cartalax operates through mechanisms that distinguish it from the majority of research peptides. Rather than engaging cell surface receptors, it acts inside the nucleus, directly modifying gene expression through DNA binding and chromatin remodeling. Researchers have identified several interlocking mechanisms operating downstream of this primary nuclear interaction.

DNA Minor Groove Binding and Transcriptional Regulation

The most fundamental mechanism studied for Cartalax involves physical binding to the minor groove of DNA at specific nucleotide sequences. Molecular modeling and spectroscopic studies from Khavinson’s group demonstrated that the Ala-Glu-Asp tripeptide forms energetically stable complexes with AT-rich DNA regions, particularly the d(ATATATATAT)2 sequence [1]. Minor groove interactions at these sites can alter local DNA conformation, influencing the accessibility of nearby promoter regions to transcription factors.

This binding mechanism positions Cartalax as a gene expression modulator that acts without dedicated receptor engagement. The charged aspartic and glutamic acid residues form electrostatic contacts with the groove’s electropositive environment, while the alanine residue contributes to structural fit. The result is sequence-selective binding that may activate or silence specific gene programs depending on the genomic context of the binding site [1,2].

Cellular Senescence Marker Downregulation

Cell culture studies have quantified Cartalax’s effects on proteins that mark and maintain the senescent state. In aging fibroblasts and kidney cells, treatment with the peptide reduced p53 expression by up to 25% [3,4]. P53 is a tumor suppressor that accumulates in senescent cells, driving cell cycle arrest through downstream effectors. Alongside p53, expression of p16 and p21, two cyclin-dependent kinase inhibitors that block cell cycle progression, also decreased in treated aging cultures [3,4].

Simultaneously, SIRT-6 expression increased in treated cells. SIRT-6 is a member of the sirtuin family of NAD-dependent deacylases, associated with genomic stability, telomere maintenance, and DNA double-strand break repair. Higher SIRT-6 activity correlates with longer lifespan in several model organisms, and its upregulation in Cartalax-treated cells represents a shift in the epigenetic landscape toward patterns more typical of younger cells [3].

Proliferation Marker Upregulation

Complementing the reduction in senescence markers, Cartalax treatment increased Ki-67 expression by 20-30% across multiple aging cell types [4,5]. Ki-67 is a nuclear protein expressed exclusively in actively dividing cells and serves as a standard proliferation marker in cell biology research. Its upregulation in aging cell cultures indicates a functional shift toward active division rather than growth arrest. CD98hc (encoded by SLC3A2), a protein associated with amino acid transport and cellular regeneration, also increased in treated cells, suggesting enhanced anabolic capacity [4].

Anti-Apoptotic Signaling

Cartalax research has also examined effects on programmed cell death. Caspase-3 activity, the primary executioner enzyme in the intrinsic apoptosis pathway, decreased in both young and aged cell cultures following Cartalax treatment [5]. This reduction in apoptotic signaling was not accompanied by evidence of oncogenic transformation in available studies, suggesting selective cytoprotection rather than broad suppression of cell death machinery. The mechanism appears to operate through altered gene expression upstream of caspase activation rather than direct enzyme inhibition.

Extracellular Matrix Homeostasis

In aging connective tissue cells, the balance between matrix synthesis and degradation shifts toward degradation, driven partly by upregulation of matrix metalloproteinases (MMPs). Cartalax research has documented suppression of MMP-9 synthesis in aging fibroblast and cartilage cultures, alongside upregulation of tissue inhibitors of metalloproteinases (TIMPs) [6]. Additional data from mechanistic studies suggest downregulation of MMP-1 and MMP-13, enzymes that degrade fibrillar collagens and are elevated in osteoarthritis models.

Simultaneously, collagen type II and proteoglycan synthesis increased in chondrocyte cultures treated with Cartalax [7]. This combination, reduced degradative enzyme activity alongside enhanced matrix synthesis, represents a net shift from catabolic to anabolic state in connective tissue cells. Researchers interpret this as evidence that Cartalax may help maintain extracellular matrix integrity during aging, though in vivo validation beyond animal models remains limited.

NF-kB Pathway Effects

Research examining Cartalax’s effects on gene expression programs associated with inflammation identified upregulation of NF-kB transcript levels in some experimental conditions [8]. NF-kB (nuclear factor kappa B) is a transcription factor complex regulating hundreds of genes involved in immune response, inflammation, and cell survival. Its upregulation in this context is not straightforwardly pro-inflammatory, as NF-kB also drives expression of anti-apoptotic and cytoprotective genes. The functional consequences of Cartalax-associated NF-kB upregulation remain incompletely characterized and represent an active area of mechanistic investigation.

Major Areas of Research

Research on Cartalax spans several biological domains, with each area building on the peptide’s core DNA-binding and gene expression-modulating properties. The following overview covers the primary research directions documented in peer-reviewed literature and preliminary investigations.

Cellular Senescence and Aging Biology

The largest body of Cartalax research addresses cellular senescence, the state in which cells permanently exit the cell cycle while remaining metabolically active and secreting inflammatory signals. Senescent cells accumulate in tissues during aging and contribute to organ dysfunction through their secretory phenotype.

Studies in aging human and rat fibroblast cultures, using immunofluorescent confocal microscopy to track protein expression across multiple passage levels, documented consistent reductions in p53, p16, and p21 alongside increases in Ki-67 and SIRT-6 [3,4]. These effects held across different passage numbers in culture, suggesting the peptide’s activity does not depend on a narrow window of cellular age. The consistency across passage levels is notable because it suggests Cartalax may influence senescence pathways regardless of how far along the aging process cells have progressed.

One important comparative finding from this research area: Cartalax demonstrated measurable activity in kidney cell cultures but showed lower potency than complex polypeptide extracts containing multiple peptide sequences [3]. This suggests the tripeptide may act synergistically with longer regulatory peptides and that its effects as an isolated compound represent a subset of the activity seen in more complex preparations.

Key Research Highlights:

• p53 expression reduced by up to 25% in aging fibroblast and kidney cell cultures
• Ki-67 proliferation marker increased by 20-30% across multiple aging cell types
• SIRT-6 upregulation indicates shift toward genomic stability and DNA repair capacity

Connective Tissue and Cartilage Biology

Cartalax research in connective tissue focuses on chondrocytes, the cells responsible for maintaining cartilage extracellular matrix. Cartilage lacks blood vessels, making it dependent on diffusion for nutrient supply and particularly vulnerable to age-related decline in cell function. Chondrocyte senescence is a recognized driver of cartilage degradation in osteoarthritis.

Studies measuring PCNA (proliferating cell nuclear antigen) expression in chondrocyte cultures from both young and aged rats showed enhanced proliferation following Cartalax treatment [7]. Type II collagen and proteoglycan synthesis, the two primary structural components of hyaline cartilage matrix, increased in treated cultures. In one rabbit cartilage defect model, peptide complexes containing Cartalax were associated with defect filling by hyaline-like cartilage rather than the inferior fibrocartilage typically seen in spontaneous repair [7]. Fibrocartilage lacks the biomechanical properties of hyaline cartilage, making the distinction clinically relevant in orthopedic contexts.

The MMP-9, MMP-1, and MMP-13 suppression documented in cartilage cultures complements these proliferation findings by reducing the enzymatic degradation that would otherwise limit matrix accumulation [6].

Key Research Highlights:

• Enhanced chondrocyte proliferation measured by PCNA in young and aged rat cell models
• Increased type II collagen and proteoglycan synthesis in treated cartilage cultures
• Hyaline-like cartilage repair in rabbit defect models treated with peptide complexes containing Cartalax

Kidney Cell Aging and Renal Biology

Kidney tissue provided one of the original research contexts for Cartalax, and renal cell aging studies have examined the peptide’s capacity to influence nephron cell proliferation and senescence marker expression. Kidney function declines with age partly due to accumulation of senescent tubular epithelial cells that reduce regenerative capacity following injury.

Chalisova and colleagues documented increased proliferation in kidney tissue cultures from both young and old animals following Cartalax exposure, alongside decreased expression of p53, p16, and p21 in aging renal cells [3]. SIRT-6 upregulation in these cells suggests improved capacity for DNA repair, a relevant finding given that kidney cells face substantial oxidative stress during normal organ function. These results position kidney cell research as a parallel track to the fibroblast studies, with converging findings across cell types despite different tissue origins.

Key Research Highlights:

• Increased proliferation in kidney tissue cultures from young and aged animal models
• Consistent senescence marker reduction (p53, p16, p21) in renal cell aging studies
• SIRT-6 upregulation indicating improved DNA repair pathway activation

Mesenchymal Stem Cell Research

Mesenchymal stem cells (MSCs) serve as progenitors for connective tissue cell types including chondrocytes, osteoblasts, and fibroblasts. Their regenerative capacity declines with aging, partly through accumulation of epigenetic changes that restrict differentiation potential and drive senescence. Research from Ashapkin and colleagues examined Cartalax effects on gene expression in aging bone marrow-derived MSCs [8].

Gene expression changes of 1.6- to 5.6-fold were documented for several targets with direct relevance to stem cell aging, including IGF1 (insulin-like growth factor 1), FOXO1 (a transcription factor controlling stress resistance and longevity pathways), TERT (telomerase reverse transcriptase, responsible for telomere maintenance), TNKS2 (tankyrase-2, involved in telomere regulation), and NF-kB [8]. The magnitude of these changes and the biological significance of the specific targets make MSC research one of the more mechanistically informative branches of Cartalax investigation, as these genes sit at the intersection of aging, stem cell maintenance, and tissue regeneration.

Key Research Highlights:

• Gene expression changes of 1.6- to 5.6-fold in aging MSCs for IGF1, FOXO1, TERT, TNKS2, and NF-kB
• Effects on telomerase regulation suggest potential relevance to stem cell longevity research
• Modulation of differentiation-associated gene programs in bone marrow progenitor cells

Dermatological and Skin Aging Research

Dermal fibroblasts produce the collagen, elastin, and glycosaminoglycans that give skin its structural properties. Their declining function during aging contributes to skin thinning, reduced wound repair capacity, and loss of elasticity. Cartalax research in dermatological contexts builds on the fibroblast senescence studies, extending findings to skin-specific functional outcomes.

Published work by Khavinson and colleagues examined Cartalax effects in skin aging models, documenting improvements in fibroblast proliferative activity, microcirculation markers, and functional output in aging skin cell cultures [5]. The reduction in apoptotic signaling in dermal fibroblasts is particularly relevant to wound healing research, as fibroblast survival following injury determines the tissue’s capacity to complete repair. Investigations in this area are less numerous than the cartilage and kidney studies but represent an active research direction.

Key Research Highlights:

• Enhanced proliferative activity in aging dermal fibroblast cultures
• Improved functional markers in skin aging models
• Reduced apoptotic signaling in fibroblasts relevant to wound repair research

Epigenetic and DNA Interaction Research

A distinct strand of Cartalax research examines the DNA-peptide interaction itself rather than downstream biological outcomes. Molecular modeling studies have characterized the geometry and energetics of Cartalax binding to AT-rich DNA sequences, establishing the physical basis for its proposed transcriptional mechanism [1,2]. These studies use computational methods alongside spectroscopic validation to map which DNA sequences bind the peptide most favorably and what conformational changes occur upon binding.

This mechanistic research is foundational for interpreting the gene expression data from cell culture studies. If Cartalax selectively stabilizes or distorts specific promoter regions, the downstream transcriptional effects become predictable from the binding specificity rather than appearing as a nonspecific consequence of peptide exposure. Understanding this selectivity is essential for assessing whether Cartalax could serve as a tool for studying specific gene regulatory networks in aging research.

Key Research Highlights:

• Molecular modeling identifies d(ATATATATAT)2 as primary DNA binding target
• Electrostatic interactions between acidic residues and minor groove established computationally and spectroscopically
• Structural basis for tissue-specific gene regulation under active investigation

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

Cartalax’s small molecular size (333 daltons) is the defining pharmacokinetic feature. At this molecular weight, the peptide does not require receptor-mediated endocytosis or active transport systems to enter cells. In rodent studies, rapid cellular penetration was observed within minutes of administration, with nuclear localization confirmed histologically, consistent with the proposed DNA-binding mechanism.

Oral administration has been explored, including capsule formulations described in Russian clinical research literature. Oral bioavailability of short peptides is generally limited by proteolytic degradation in the gastrointestinal tract, though the relatively simple three-amino-acid structure offers fewer cleavage sites than longer sequences. Sublingual delivery has also been investigated as a route that bypasses gastrointestinal exposure, allowing direct mucosal absorption. Formal bioavailability studies comparing administration routes in controlled experimental settings have not been published in the peer-reviewed literature to date.

Distribution and Metabolism

Following administration in animal models, Cartalax distributes to multiple target tissues including skin, kidney, cartilage, and connective tissues. Nuclear localization within these tissues is consistent with the proposed intranuclear mechanism of action. The peptide crosses both plasma membranes and nuclear envelopes, which distinguishes its distribution pattern from larger peptides that remain primarily extracellular or cytoplasmic.

Plasma half-life has not been formally characterized in published studies. Presumed rapid clearance through standard peptidase pathways is inferred from the peptide’s structure rather than measured directly. The most pharmacokinetically distinctive aspect of Cartalax research is the disconnect between presumed short plasma residence time and biological effects that persist for hours to days after administration. Researchers attribute this persistence to the gene expression changes triggered at the nuclear level, which continue producing functional protein products long after the peptide itself has been cleared [2].

Delivery Methods Under Investigation

• Subcutaneous injection: Most common route in published animal aging studies; provides systemic delivery with predictable absorption
• Intraperitoneal injection: Used in rodent models for precise dosing; enables rapid systemic distribution
• Oral administration: Investigated in some research contexts; bioavailability limited by gastrointestinal proteolysis
• Sublingual delivery: Explored for direct mucosal absorption bypassing gastrointestinal exposure

Excretion and Clearance

Elimination of Cartalax and its metabolic breakdown products is presumed to occur through renal excretion of the component amino acids following peptidase-mediated degradation, consistent with the metabolic fate of other short peptides. No evidence of tissue accumulation has been detected in animal studies involving repeated dosing. Comprehensive excretion kinetics, including formal measurement of plasma clearance rates, metabolite identification, and tissue half-life, have not been published and represent a significant gap in the available pharmacokinetic data.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data The most significant limitation in Cartalax research is the near-complete absence of human clinical trial data. No Phase II or Phase III randomized controlled trials have been published or registered in major international trial registries. Some use of bioregulatory peptides including Cartalax is described in Russian clinical research literature, but these reports lack the controlled design, sample sizes, and blinding required to establish safety or efficacy. Human pharmacokinetics, tissue distribution, and systemic effects in people are essentially unknown.

Mechanistic Characterization While the DNA minor groove binding mechanism is supported by molecular modeling and cell culture data, direct experimental confirmation of the proposed gene regulatory cascade in living tissue remains limited. The connection between DNA binding at specific AT-rich sequences and the observed changes in p53, SIRT-6, and MMP-9 expression has not been traced through a continuous experimental chain. It remains possible that some cellular effects occur through secondary mechanisms not yet identified.

Comparative Potency and Synergy One published finding noted that Cartalax showed lower potency than complex polypeptide extracts in kidney cell cultures, suggesting the isolated tripeptide may represent only part of the activity seen in multi-peptide formulations [3]. The conditions under which Cartalax might act synergistically with other peptide sequences, and which combinations produce additive versus diminishing effects, have not been systematically studied.

Methodological Considerations Most published research originates from a single research group centered around Professor Khavinson’s institute, limiting independent replication. Study designs rely heavily on cell culture systems and rodent models. The biological relevance of in vitro concentrations and in vivo animal doses to human physiology cannot be established without dedicated translational studies. Variation in dosing protocols across studies also limits meta-analytic synthesis of results.

Areas Needing Further Investigation

• Human pharmacokinetic studies establishing plasma half-life, bioavailability by route, and tissue distribution in people
• Independent replication of cell culture findings by research groups unaffiliated with the original investigators
• Long-term safety assessment beyond the durations used in existing animal studies
• Direct mechanistic tracing from DNA binding events to specific downstream gene expression changes in intact tissue
• Formal dose-response studies establishing concentration-effect relationships across cell types and species

Regulatory and Research Status

Current Classification

FDA Status Cartalax is not approved by the FDA for any human therapeutic application. It is classified as a research chemical and is available solely for use in legitimate laboratory and preclinical research settings. The FDA has not issued specific regulatory guidance documents addressing Cartalax individually. Its status as an unapproved new drug under federal law means it cannot be legally marketed or sold for human consumption in the United States.

WADA Status Cartalax does not appear on the current World Anti-Doping Agency prohibited list by name. However, its classification as a peptide bioregulator with potential effects on cell proliferation and gene expression means it could fall under broader prohibited substance categories depending on context and future regulatory decisions. Researchers and institutions working with this compound in athletic research contexts should consult current WADA technical documents for applicable peptide categories.

International Perspective In Russia, where the foundational research was conducted, bioregulatory peptides developed through Khavinson’s program have received broader regulatory consideration than in Western markets. Some peptide bioregulators have been approved as dietary supplements or pharmaceuticals in Russia, though Cartalax specifically remains classified for research use in most international jurisdictions. The European Medicines Agency has not approved Cartalax for any indication. Regulatory status for veterinary applications varies across markets.

Research Community Approach

Active investigation of Cartalax continues primarily through academic research institutions, with most published work originating from the St. Petersburg Institute of Bioregulation and Gerontology. Research requires institutional approval, appropriate biosafety protocols for handling research chemicals, and compliance with applicable regulations governing animal studies and cell culture work. Independent replication of findings by additional research groups would significantly strengthen the evidence base.

Future Research Directions

The path from current preclinical data to any clinical application requires, at minimum, formal human pharmacokinetic studies, toxicology assessment, and proof-of-concept clinical trials. The mechanistic specificity suggested by the DNA-binding data provides a scientific rationale for continued investigation, particularly in the context of aging biology where transcriptional regulators of senescence are an active drug development target. Whether Cartalax or related short bioregulatory peptides can reach the evidentiary threshold required for clinical development remains an open question dependent on future research investment and independent validation.

Key Research Findings

Molecular Modeling of DNA-Peptide Interaction

Research Focus: Characterization of Cartalax binding to DNA minor groove sequences Key Results: Molecular modeling identified d(ATATATATAT)2 as the preferred binding target; energetically favorable complexes confirmed through computational analysis; electrostatic contacts between acidic residues and minor groove established Significance: Establishes physical basis for proposed transcriptional mechanism and distinguishes Cartalax from receptor-targeting peptides Limitations: Computational modeling requires experimental validation; binding in intact chromatin context not fully characterized [1,2]

Senescence Marker Reduction in Aging Fibroblasts

Research Focus: Effects of Cartalax on p53, p16, p21, Ki-67, and CD98hc expression in aging human and rat fibroblast cultures Key Results: p53 reduced by up to 25%; p16 and p21 decreased; Ki-67 increased 20-30%; CD98hc upregulated; effects consistent across multiple passage numbers using immunofluorescent confocal microscopy Significance: Provides quantified evidence for a shift in gene expression profile from senescent toward proliferative state in aging cells Limitations: Cell culture conditions; results require validation in intact tissue and animal aging models before extrapolation [4,5]

Kidney Cell Aging and SIRT-6 Upregulation

Research Focus: Cartalax effects on proliferation and senescence markers in renal cell cultures from young and aged animals Key Results: Increased proliferation in cultures from both age groups; decreased p53, p16, and p21 in aging cells; SIRT-6 upregulated, suggesting enhanced DNA repair capacity; Cartalax less potent than complex polypeptide extracts Significance: Extends senescence findings to renal cell biology and introduces SIRT-6 as a mechanistic target; comparative potency data provides important context for blend research Limitations: Animal-derived cell cultures; human renal biology differences not addressed; single research group [3]

Chondrocyte Proliferation and Cartilage Matrix Studies

Research Focus: Cartalax effects on chondrocyte proliferation and extracellular matrix synthesis in young and aged rat models, including rabbit cartilage defect investigation Key Results: Enhanced chondrocyte proliferation by PCNA measurement; increased type II collagen and proteoglycan synthesis; rabbit defect model showed hyaline-like rather than fibrocartilage repair with peptide complex treatment Significance: Most directly relevant findings for connective tissue research applications; hyaline cartilage repair distinction has clear functional implications Limitations: Rabbit data used peptide complexes rather than isolated Cartalax; species differences limit direct translation; no human cartilage data [7]

Mesenchymal Stem Cell Gene Expression Profiling

Research Focus: Gene expression changes in aging bone marrow-derived mesenchymal stem cells following Cartalax treatment Key Results: 1.6- to 5.6-fold changes in expression of IGF1, FOXO1, TERT, TNKS2, and NF-kB; effects on telomerase and longevity-associated transcription factors documented Significance: Implicates Cartalax in stem cell aging biology and connects its activity to telomere maintenance and stress resistance pathways; among the most mechanistically informative published studies Limitations: Gene expression changes require functional validation; downstream protein-level effects and stem cell behavior outcomes not fully characterized [8]

MMP Suppression and ECM Homeostasis

Research Focus: Effects on matrix metalloproteinase expression and tissue inhibitor of metalloproteinase upregulation in aging connective tissue cells Key Results: MMP-9 suppression confirmed; additional downregulation of MMP-1 and MMP-13 noted; TIMP upregulation documented; net shift from catabolic to anabolic matrix state Significance: Provides mechanistic explanation for cartilage matrix protection findings; directly relevant to osteoarthritis research where MMP dysregulation drives degradation Limitations: In vitro findings; MMP inhibition in intact joint tissue under mechanical loading conditions not yet investigated [6]

Frequently Asked Questions

What is Cartalax and what makes it different from other research peptides?

Cartalax is a synthetic tripeptide made of three amino acids (alanine, glutamic acid, and aspartic acid) that is studied for its ability to enter cell nuclei and bind directly to DNA. Most research peptides work by attaching to receptors on the outside of cells, but Cartalax is small enough to cross directly into the nucleus and interact with gene regulatory regions, which makes it a subject of interest in epigenetics and aging research.

What types of cells and tissues have been studied with Cartalax?

Researchers have studied Cartalax in dermal fibroblasts, kidney epithelial cells, chondrocytes (cartilage cells), bone marrow-derived mesenchymal stem cells, and various connective tissue models. Cell culture studies from both young and aged animals have been used, along with cartilage defect models in rabbits. The research is preclinical, with no published human clinical trial data.

What does the research show about Cartalax and cellular aging?

Cell culture studies show that Cartalax treatment is associated with reduced expression of aging-related proteins including p53, p16, and p21, alongside increased expression of the proliferation marker Ki-67 and the longevity-associated protein SIRT-6. These shifts suggest the peptide may influence the molecular state of aging cells, though whether these in vitro findings translate to meaningful effects in living organisms remains an open research question.

How long has Cartalax been studied and who developed it?

Cartalax was developed in the 1990s by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Khavinson’s group developed an extensive program of short bioregulatory peptides derived from organ and tissue extracts, with Cartalax being one of several peptides from this research lineage. Published studies on Cartalax span from the early 2000s through recent years, with ongoing research in cellular aging and connective tissue biology.

Is Cartalax approved for any medical use?

Cartalax is not approved for human therapeutic use by the FDA, EMA, or other major regulatory agencies. It is classified as a research chemical available for laboratory and preclinical research purposes only. Some bioregulatory peptides from the same research program have received regulatory consideration in Russia, but Cartalax specifically is classified for research use in international markets. No registered human clinical trials have been published.

References

1. Khavinson, V.K., Lezhava, T.A., Monaselidze, J.R., Jokhadze, T.A., Dvalishvili, N.A., Bablishvili, N.K., & Torigoe, C. (2003). Peptide Ala-Glu-Asp-Gly inhibits DNA methylation and histone acetylation in chromatin. Neuro Endocrinology Letters, 24(5), 356-358. PubMed

2. Khavinson, V.K., Tarnovskaya, S.I., Linkova, N.S., Chervyakova, N.A., Ivko, O.M., Nichik, T.E., Elashkina, E.V., & Gutop, E.O. (2013). Short cell-penetrating peptides: a model of interactions with gene promoter sites. Bulletin of Experimental Biology and Medicine, 154(6), 761-764. PubMed

3. Chalisova, N.I., Lin’kova, N.S., Nichik, T.E., Rudanova, E.E., Rebeko, M.V., & Khavinson, V.K. (2015). Short peptides stimulate kidney tissue cell renewal in old age. Bulletin of Experimental Biology and Medicine, 159(6), 784-787. PubMed

4. Lin’kova, N.S., Kozhevnikova, E.O., Nichik, T.E., Chervyakova, N.A., Kostylev, A.V., & Khavinson, V.K. (2016). Peptide regulation of skin fibroblast functions during aging. Bulletin of Experimental Biology and Medicine, 161(1), 175-178. PubMed

5. Khavinson, V.K., Linkova, N.S., Kozhevnikova, E.O., & Trofimova, S.V. (2020). Short peptides: regulation of skin function during aging. Advances in Gerontology, 33(1), 46-54. PubMed

6. Chalisova, N.I., Simbirtsev, A.S., Martynyuk, V.P., Lin’kova, N.S., Nichik, T.E., Kozhevnikova, E.O., Kostylev, A.V., & Khavinson, V.K. (2014). Short peptides stimulate cell regeneration in tissue culture during ageing. Advances in Gerontology, 27(1), 62-67. PubMed

7. Linkova, N.S., Khavinson, V.K., Umnov, R.S., Kalinina, N.M., Moreiko, I.V., Myakisheva, S.N., & Nichik, T.E. (2023). Peptide bioregulators in chondrocyte aging and degenerative joint disease. Biogerontology, 24(2), 179-193. PubMed

8. Ashapkin, V.V., Kutueva, L.I., Vanyushin, B.F., & Khavinson, V.K. (2020). Peptide-induced epigenetic changes in aging mesenchymal stem cells. Biogerontology, 21(5), 651-663. PubMed

9. Chalisova, N.I., Lin’kova, N.S., & Khavinson, V.K. (2015). Comparison of effects of short peptide regulators on kidney tissue cell culture in young and old rats. Advances in Gerontology, 28(4), 669-673. PubMed

10. Khavinson, V.K., Tarnovskaia, S.I., & Lin’kova, N.S. (2014). Tripeptides slow down aging process in renal cell culture. Bulletin of Experimental Biology and Medicine, 157(2), 237-240. PubMed

11. Ashapkin, V.V., Kutueva, L.I., Vanyushin, B.F., & Khavinson, V.K. (2021). Epigenetic mechanisms of peptide-induced rejuvenation of aging stem cells. International Journal of Molecular Sciences, 22(24), 13571. PubMed

12. Linkova, N.S., Myakisheva, S.N., Nichik, T.E., Kostylev, A.V., Umnov, R.S., Moreiko, I.V., & Khavinson, V.K. (2023). Short peptide Ala-Glu-Asp regulates chondrogenesis and chondrocyte aging. Cells, 12(8), 1193. PubMed

13. Myakisheva, S.N., Linkova, N.S., Trofimova, S.V., & Khavinson, V.K. (2023). Peptide bioregulation of extracellular matrix homeostasis in cartilage aging. International Journal of Molecular Sciences, 24(11), 9614. PubMed

14. Chalisova, N.I., Linkova, N.S., Trofimova, S.V., & Khavinson, V.K. (2014). Regulation of fibroblast function and matrix metalloproteinase expression by short peptides in aging skin models. Advances in Gerontology, 27(3), 450-456. PubMed

15. Khavinson, V.K., Linkova, N.S., Kozhevnikova, E.O., Trofimova, S.V., & Tendler, S.M. (2021). Bioregulatory peptides: from structure to function. Current Medicinal Chemistry, 28(19), 3771-3781. PubMed

16. Linkova, N.S., Khavinson, V.K., Diatlova, A.S., & Trofimova, S.V. (2021). Peptide bioregulators: the new chapter in the anti-aging medicine. Biomedicines, 9(10), 1386. PubMed

17. Gutop, E.O., Linkova, N.S., Nichik, T.E., Kozhevnikova, E.O., Trofimova, S.V., & Khavinson, V.K. (2019). Peptide regulation of cell proliferation and apoptosis in aging fibroblast cultures. Advances in Gerontology, 32(6), 955-961. PubMed